lixiana.co.uk lixiana.co.uk - LIXIANA? (edoxaban) | Official Site for Healthcare Professionals

lixiana.co.ukWebsite Profile

Title: LIXIANA? (edoxaban) | Official Site for Healthcare Professionals
Keywords:
Description:LIXIANA? (edoxaban) | Official Site for Healthcare Professionals It looks like you have Javascript turned off. For the site to work properly please go to your settings and enable javascript. Once you'
lptelecom.ca is ranked 25408406 in the world (amongst the 40 million domains). A low-numbered rank means that this website gets lots of visitors. This site is relatively popular among users in the united states. It gets 50% of its traffic from the united states .This site is estimated to be worth $2,503. This site has a low Pagerank(0/10). It has 1 backlinks. lptelecom.ca has 43% seo score.

lixiana.co.uk Information

Website / Domain:lixiana.co.uk
Website IP Address:40.118.104.64
Domain DNS Server:ns1.daiichi-dns.de,ns2.daiichi-dns.de

lixiana.co.uk ranks

Alexa Rank:10957894
EveryoneDomain Rank:1
Google Page Rank:0/10 (Google Pagerank Has Been Closed)

lixiana.co.uk Traffic & Earnings

Purchase/Sale Value:$10,283
Daily Revenue:$28
Monthly Revenue:$845
Yearly Revenue:$$10,283
Daily Unique Visitors:2,592
Monthly Unique Visitors:77,760
Yearly Unique Visitors:946,080

lixiana.co.uk WebSite Httpheader

StatusCode 200
Cache-Control private
Content-Type text/html; charset=utf-8
Server Microsoft-IIS/8.5
Date Wed, 17 Oct 2018 17:14:12 GMT

lixiana.co.uk WebSite Httpheader

Keyword Count Percentage

lixiana.co.uk Similar Website

Domain WebSite Title
lixiana.com LIXIANA? (edoxaban) | Official Site for Healthcare Professionals
savaysahcp.com Healthcare Professional Site | SAVAYSA? (edoxaban) | HCP
lixiana.de LIXIANA? (Edoxaban) - Offizielle Seite für medizinisches Fachpersonal
novoeightpro.com Novoeight? Healthcare Professionals | Official Site
nulojix.com NULOJIX? (belatacept)-Official Site For US Healthcare Professionals
savaysa.com Patient Site | SAVAYSA? (edoxaban)
lixianapatient.com LIXIANA
vonvendipro.com VONVENDI [von Willebrand factor (Recombinant)]: Official Healthcare Professionals Site
adynovatepro.com ADYNOVATE? [Antihemophilic Factor (Recombinant), PEGylated] Official Healthcare Professionals Site
hepbmd.com HepBMD.com | Official Site – Chronic Hepatitis B Education for Healthcare Professionals
velcade-hcp.com VELCADE? (bortezomib) | Official Website for Healthcare Professionals
vidaza.net Vidaza.net Vidaza? (Azacitidine) | International Site for Healthcare Professionals
antiplatelets2016.eu THIS SITE IS FOR HEALTHCARE PROFESSIONALS ONLY | ESC Effient 2016
vivitrolhcp.com VIVITROL? | Official Healthcare Professional Site
transformingtreatment.com Official Healthcare Professional (HCP) Site
omronhealthcare.com.ph Omron Healthcare Philippines - Official Site
alprolixpro.com Official Healthcare Provider Site | ALPROLIXpro.com
eloctatepro.com Official Healthcare Provider Site | ELOCTATEpro.com

lixiana.co.uk Alexa Rank History Chart

lixiana.co.uk aleax

lixiana.co.uk Html To Plain Text

LIXIANA? (edoxaban) | Official Site for Healthcare Professionals It looks like you have Javascript turned off. For the site to work properly please go to your settings and enable javascript. Once you've enabled javascript try reloading this page. Enter LIXIANA? International Site SearchClose PI and AE reporting Home Dosing Dosing overview Switching to and from other anticoagulants Treating special populations Practical considerations Efficacy and safety Efficacy and safety overview Nonvalvular atrial fibrillation (NVAF) Efficacy in NVAF Safety in NVAF Venous thromboembolism (VTE) Efficacy in VTE Safety in VTE Clinical trials Clinical trials overview ENGAGE AF-TIMI 48 trial Hokusai-VTE trial Practical guide Practical guide overview Dosing and dose reductions Switching to and from LIXIANA? Contraindications Special populations Perioperative management Temporary discontinuation or overdose Adverse events Bleeding complications Coagulation testing Patient alert card Healthcare professional resources Healthcare professional resources overview Practical guide Journal articles Core slide decks Patient Support Materials SPC Contact us Terms and conditions Sitemap Daiichi Sankyo Once-daily LIXIANA? – an oral, direct factor Xa inhibitor indicated for1: Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults VIEW PRACTICAL GUIDE Now NICE recommended and SMC accepted in NVAF and VTE2-5 GO TO NVAF SMC GUIDANCE PAGE GO TO VTE SMC GUIDANCE PAGE GO TO NVAF NICE GUIDANCE PAGE GO TO VTE NICE GUIDANCE PAGE Simple and convenient once-daily dosing Once-daily dosing, with or without food – consistent across both nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE*) indications.1 GO TO LIXIANA? DOSING INFORMATION Efficacy and safety data Demonstrated in two large Phase 3 clinical trials in nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE).6,7 SEE MORE GO TO THE EFFICACY AND SAFETY OVERVIEW LIXIANA? – proven efficacy comparable to well-controlled warfarin in the prevention of stroke and systemic embolism (SEE) in nonvalvular atrial fibrillation (NVAF) patients4 SEE THE EFFICACY RESULTS IN NVAF PATIENTS Superior reduction in major bleeding vs. well-controlled warfarin in NVAF patients**4 SEE SAFETY DATA IN NVAF PATIENTS LIXIANA? – proven efficacy comparable to well-controlled warfarin in the treatment and prevention of recurrent venous thromboembolism (VTE), following the initial use of heparin for at least 5 days5 SEE THE EFFICACY RESULTS IN VTE PATIENTS Superior reduction in clinically relevant bleeding vs. well-controlled warfarin in VTE patients?5 SEE THE SAFETY DATA IN VTE PATIENTS Close Clinical trial designs Robust clinical trials designed to reflect the nonvalvular atrial fibrillation (NVAF), deep vein thrombosis (DVT) and pulmonary embolism (PE) patients you may see in your daily clinical practice.6,7 SEE MORE SEE THE CLINICAL TRIALS OVERVIEW ENGAGE AF-TIMI 48 trial ENGAGE AF-TIMI 48 was the largest (21,105 patients) and longest (2.8 years median follow up) comparative NVAF trial to date with a NOAC (non-Vitamin K antagonist anticoagulant)4 LEARN ABOUT THE ENGAGE AF-TIMI 48 TRIAL Hokusai-VTE trial Hokusai-VTE was the largest (8,292 patients) single comparative VTE (DVT and/or PE) trial to date5 LEARN ABOUT THE HOKUSAI-VTE TRIAL Close Practical guide Practical guidance to support you when prescribing LIXIANA?. SEE MORE Practical guidance for prescribing LIXIANA? View important practical information including dosing and switching, patients at higher risk of bleeding, special populations, management of bleeding complications and what to do if a patient overdoses or misses a dose. VIEW PRACTICAL GUIDANCE Close Healthcare professional resources Download useful resources to use in your practice and view journal articles. GO TO HEALTHCARE PROFESSIONAL RESOURCES Contact us If you are based in the UK and have any questions about LIXIANA?, Daiichi Sankyo or this website, please get in touch. CONTACT US NOW Indications Introducing once-daily LIXIANA? (edoxaban) – an oral, direct factor Xa inhibitor indicated for:1 ? Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA) ? Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT or PE in adults Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT or PE in adults Now NICE recommended and SMC accepted in NVAF and VTE2-5 Now NICE recommended and SMC accepted in NVAF and VTE2-5 Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with NVAF, and for treating and preventing recurrent DVT and PE in adults.2,3 NVAFVTE Dosing Information Dosing information Once-daily dosing, with or without food – consistent across both NVAF and VTE* indications. 1 Practical guide Practical guide Practical guidance to support you when prescribing LIXIANA? Healthcare professional resources Healthcare professional resources Download useful resources to use in your practice and view journal articles Efficacy and Safety Efficacy and Safety Proven efficacy comparable to well-controlled warfarin in nonvalvular atrial fibrillation (NVAF), with a superior reduction in major bleeding6 Proven efficacy comparable to well-controlled warfarin in venous thromboembolism (VTE), with a superior reduction in clinically relevant bleeding7 NVAFVTE Clinical Trials ENGAGE AF-TIMI 48: Largest and longest comparative NVAF trial to date with a NOAC (non-Vitamin K antagonist oral anticoagulant).6 ENGAGE AF-TIMI 48 Hokusai-VTE is the largest single comparative VTE trial to date with a NOAC (non-Vitamin K antagonist oral anticoagulant).7 Hokusai-VTE Contact us Contact us If you are based in the UK and have any questions about LIXIANA?, Daiichi Sankyo or this website, please get in touch. FOOTNOTES FOOTNOTES * Following initial use of heparin for at least 5 days ** The primary safety endpoint of ENGAGE AF-TIMI 48 was the incidence of adjudicated major bleeding, defined by the International Society on Thrombosis and Haemostasis (ISTH) as (i) fatal bleeding; and/or (ii) symptomatic bleeding in critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome, and/or (iii) bleeding causing a fall in haemoglobin level of 2.0 g/dL or more, or leading to transfusion of two or m...

lixiana.co.uk Whois

Domain Name: LIXIANA.CO.UK


The data contained in Everyone.domains, LLC's WhoIs database,
while believed by the company to be reliable, is provided "as is"
with no guarantee or warranties regarding its accuracy. This
information is provided for the sole purpose of assisting you
in obtaining information about domain name registration records.
Any use of this data for any other purpose is expressly forbidden without the prior written
permission of EveryOne.domains, LLC.By submitting an inquiry,
you agree to these terms of usage and limitations of warranty.In particular,
you agree not to use this data to allow, enable, or otherwise make possible,
dissemination or collection of this data, in part or in its entirety, for any
purpose, such as the transmission of unsolicited advertising and
and solicitations of any kind, including spam.You further agree
not to use this data to enable high volume, automated or robotic electronic
processes designed to collect or compile this data for any purpose,
including mining this data for your own personal or commercial purposes.


Please note: the registrant of the domain name is specified
in the "registrant" section.In most cases, Everyone.domains, LLC
is not the registrant of domain names listed in this database.";

For more information on Whois status codes, please visit
https://www.icann.org/resources/pages/epp-status-codes-2014-06-16-en